Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Aurinia Pharmaceuticals Inc AUPH

Aurinia Pharmaceuticals Inc. is a fully integrated biopharmaceutical company. The Company is focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. It has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct clinical and regulatory activities to support the LUPKYNIS development program. The Company is primarily engaged in the development of its pipeline asset AUR200, a differentiated, potential next generation therapy for autoimmune diseases that targets both BAFF (B-cell Activating Factor) and APRIL (A Proliferation-Inducing Ligand). The Company contracted with Otsuka Pharmaceutical Co., Ltd. (Otsuka) as a collaboration partner for the development and commercialization of LUPKYNIS in the Otsuka Territories. It sells LUPKYNIS (voclosporin) primarily to specialty pharmacies and a specialty distributor and directly to its ex-U.S. partner, Otsuka.


NDAQ:AUPH - Post by User

Bullboard Posts
Post by Moneyday0on Aug 18, 2016 8:49am
289 Views
Post# 25153317

Huge volume moves past days in US

Huge volume moves past days in USAug 15 - 11,892,637 Aug 16 - 17,892,675 Aug 17 - 7,433,982 Add TMX moves and pretty significant turn over of ownership. See Zacks still trying to correlate the mid-stage results as being cause for the 13 deaths. However it still remains a strong buy on their system (strange right). Nice to see Cannacord and others reiterate buys and up their target prices. Certainly provides confidence that results were significant and not just encouraging despite attempts by zacks to headline the unrelated deaths over the real results.
Bullboard Posts